Confirmed Vivax Resistance to Chloroquine and Effectiveness of Artemether-lumefantrine for the Treatment of Vivax Malaria in Ethiopia

Overview

Journal Am J Trop Med Hyg

Specialty Tropical Medicine

Date 2011 Jan 8

PMID 21212216

Citations 33

Authors

Ambachew M Yohannes

Awash Teklehaimanot

Yngve Bergqvist

Pascal Ringwald

Affiliations

Soon will be listed here.

Abstract

Chloroquine (CQ) is still the drug of choice for the treatment of vivax malaria in Ethiopia, whereas artemether-lumefantrine (AL) is for falciparum malaria. In this setting, clinical malaria cases are treated with AL. This necessitated the need to assess the effectiveness of AL for the treatment of Plasmodium vivax with CQ as a comparator. A total of 57 (80.3%) and 75 (85.2%) cases treated with CQ or AL, respectively, completed the study in an outpatient setting. At the end of the follow-up period of 28 days, a cumulative incidence of treatment failure of 7.5% (95% confidence interval [CI] = 2.9-18.9%) for CQ and 19% (95% CI = 11-31.6%) for AL was detected. CQ resistance was confirmed in three of five CQ treatment failures cases. The effectiveness of AL seems lower than CQ; however, the findings were not conclusive, because the AL evening doses were not supervised.

Citing Articles

Investigation of Mutations in the and Genes of for the Molecular Surveillance of Chloroquine Resistance in Parasites from Gold Mining Areas in Roraima, Brazil.

de Aguiar Barros J, Granja F, Abreu-Fernandes R, de Queiroz L, E Silva D, Cito A Microorganisms. 2024; 12(8).

PMID: 39203521 PMC: 11356832. DOI: 10.3390/microorganisms12081680.

Therapeutic efficacy of Chloroquine for the treatment of uncomplicated Plasmodium vivax infection in Shewa Robit, Northeast Ethiopia.

Belay H, Alemu M, Hailu T, Mohammed H, Sime H, Hailegeorgies H PLoS One. 2023; 18(1):e0277362.

PMID: 36634046 PMC: 9836259. DOI: 10.1371/journal.pone.0277362.

Efficacy and safety of pyronaridine-artesunate (Pyramax) for the treatment of uncomplicated Plasmodium vivax malaria in Northwest Ethiopia.

Mohammed H, Sime H, Hailgiorgis H, Chernet M, Alebachew M, Solomon H Malar J. 2022; 21(1):401.

PMID: 36587210 PMC: 9805271. DOI: 10.1186/s12936-022-04422-0.

Therapeutic efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium vivax malaria in Seacha area, Arbaminch Zuria District, South West Ethiopia.

Mohammed H, Sime H, Hailgiorgis H, Gubae K, Haile M, Solomon H Malar J. 2022; 21(1):351.

PMID: 36437454 PMC: 9701447. DOI: 10.1186/s12936-022-04380-7.

In vivo efficacy of anti-malarial drugs against clinical Plasmodium vivax malaria in Ethiopia: a systematic review and meta-analysis.

Ketema T, Bacha K, Getahun K, Bassat Q Malar J. 2021; 20(1):483.

PMID: 34952581 PMC: 8709955. DOI: 10.1186/s12936-021-04016-2.

References

Baird J, Lacy M, Basri H, Barcus M, Maguire J, Bangs M . Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis. 2001; 33(12):1990-7. DOI: 10.1086/324085. View

Yeshiwondim A, Tekle A, Dengela D, Yohannes A, Teklehaimanot A . Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia. Acta Trop. 2009; 113(2):105-13. DOI: 10.1016/j.actatropica.2009.10.001. View

Jima D, Tesfaye G, Medhin A, Kebede A, Argaw D, Babaniyi O . Efficacy of sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J. 2005; 82(8):391-5. DOI: 10.4314/eamj.v82i8.9322. View

Karunajeewa H, Mueller I, Senn M, Lin E, Law I, Gomorrai P . A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med. 2008; 359(24):2545-57. DOI: 10.1056/NEJMoa0804915. View

Baird J . Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother. 2004; 48(11):4075-83. PMC: 525399. DOI: 10.1128/AAC.48.11.4075-4083.2004. View

Teklehaimanot A . Chloroquine-resistant Plasmodium falciparum malaria in Ethiopia. Lancet. 1986; 2(8499):127-9. DOI: 10.1016/s0140-6736(86)91945-8. View

Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim J, Nandy A . Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis. 2007; 195(7):927-33. DOI: 10.1086/512241. View

Baird J, Leksana B, Masbar S, Fryauff D, Sutanihardja M, Suradi . Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg. 1997; 56(6):621-6. DOI: 10.4269/ajtmh.1997.56.621. View

Jima D, Tesfaye G, Medhin A, Kebede A, Argaw D, Babaniyi O . Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J. 2005; 82(8):387-90. DOI: 10.4314/eamj.v82i8.9321. View

10.

Baird J, Sustriayu Nalim M, Basri H, Masbar S, Leksana B, Tjitra E . Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg. 1996; 90(4):409-11. DOI: 10.1016/s0035-9203(96)90526-x. View

11.

Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S . Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J. 2008; 7:220. PMC: 2584068. DOI: 10.1186/1475-2875-7-220. View

12.

Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung R, Laihad F . Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007; 369(9563):757-765. PMC: 2532500. DOI: 10.1016/S0140-6736(07)60160-3. View

13.

Tulu A, WEBBER R, Schellenberg J, Bradley D . Failure of chloroquine treatment for malaria in the highlands of Ethiopia. Trans R Soc Trop Med Hyg. 1996; 90(5):556-7. DOI: 10.1016/s0035-9203(96)90322-3. View

14.

Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q . Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis. 2007; 195(7):934-41. DOI: 10.1086/512242. View

15.

Baird J, Basri H, Subianto B, Fryauff D, McElroy P, Leksana B . Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis. 1995; 171(6):1678-82. DOI: 10.1093/infdis/171.6.1678. View

16.

Krudsood S, Tangpukdee N, Muangnoicharoen S, Thanachartwet V, Luplertlop N, Srivilairit S . Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol. 2007; 45(2):111-4. PMC: 2526312. DOI: 10.3347/kjp.2007.45.2.111. View

17.

Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E . Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet. 2005; 365(9469):1467-73. DOI: 10.1016/S0140-6736(05)66416-1. View

18.

Imwong M, Pukrittayakamee S, Gruner A, Renia L, Letourneur F, Looareesuwan S . Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J. 2005; 4:20. PMC: 1131918. DOI: 10.1186/1475-2875-4-20. View

19.

Ketema T, Bacha K, Birhanu T, Petros B . Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malar J. 2009; 8:177. PMC: 3224920. DOI: 10.1186/1475-2875-8-177. View